Atalante 1, an international registration Phase 3 trial currently ongoing

FR104, since 2013, has been included in an exclusive global license agreement with Janssen Biotech, Inc., member of Johnson & Johnson, a leading pharmaceutical Group, for indications in autoimmune diseases and transplantation.